Article · 2017
Editorial Board Member
Ken H Young
USA, Department of Hematopathology, The University of Texas MD Anderson Cancer Center
About
As published by the journal they serve.
Ken H. Young is a Professor at The University of Texas MD Anderson Cancer Center in the Department of Hematopathology. Young completed his MD at Zhejiang University School of Medicine, China in 1984. Dr. Ken primary study of genomic alterations is on TP53 tumor suppressor pathway. His secondary focus is on Myc oncogene. Weblink to MD Anderson SciVal research profile and PubMed list of publication is attached. Ken research team performs several types of hematologic malignancies, with special emphasis on pathogenesis of malignant lymphomas, especially diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive B-cell lymphoma which brings together the worst characteristics of both high-grade features and aggressive biology. The disease is incurable in nearly 40% patients. Ken has published over 134 articles in different journals. Dr. Ken has worked as committee member at American Board of Pathology, Anatomic and Clinical Pathology and American Board of Hematology. Currently, Dr. Ken is Vice-Chair for IRG Pilot Grant Review Committee at The University of Texas MD Anderson Cancer Center, Houston.
Research interests
Qualifications
PhD
Journals they serve
The seats these journals name them in.
- Advanced Biomedical Research and InnovationEditorial Board Member
Articles we hold
Articles in the journals they serve whose byline carries this name.
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.
